Medtronic plc Stock
Medtronic plc Stock
Pros and Cons of Medtronic plc in the next few years
Pros
Cons
Performance of Medtronic plc vs. its peers
| Security | Change(%) | 1w | 1m | 1y | YTD | 3y | 5y |
|---|---|---|---|---|---|---|---|
| Medtronic plc | 0.460% | -1.108% | -0.253% | -3.226% | 0.321% | -28.707% | -9.639% |
| Dentsply Sirona Inc. | 0.390% | 1.935% | -8.215% | -23.639% | -19.795% | -52.850% | -46.463% |
| Dexcom Inc. | -1.720% | -6.730% | -8.293% | -0.273% | -2.215% | 44.100% | 305.481% |
| Zimmer Holdings | -0.330% | -1.164% | -6.561% | -10.990% | -3.545% | -21.232% | 3.290% |
sharewise BeanCounterBot
The analysis provided is generated by an artificial intelligence system and is provided for informational purposes only. We do not guarantee the accuracy, completeness, or usefulness of the analysis, and we are not responsible for any errors or omissions. Use of the analysis is at your own risk.Upon first glance at Medtronic's financials, the company appears to be a strong player in the Healthcare Equipment & Supplies sector. Over the years, Medtronic has demonstrated relatively stable financial performance, which is a desirable attribute for a healthcare company. However, more in-depth analysis is needed to better understand the pros and cons of its financial situation.
Revenue Growth: Medtronic's total revenue has experienced consistent growth over the last three years as seen in the yearly income statements. In 2020, the company recorded total revenue of $28.913 billion which increased to $30.117 billion in 2021, and further to $31.686 billion in 2022.
Increasing Gross Profit: Medtronic has seen a rise in its gross profit, from $19.489 billion in 2020 to $19.634 billion in 2021, and eventually $21.541 billion in 2022. This implies that the company is becoming more efficient in its manufacturing and supply chain activities, which is a good sign for potential investors.
Comments
News
Is Medtronic Stock a Buy?
Medtronic (NYSE: MDT) is a top healthcare company and a leading maker of medical devices. At a market cap of more than $100 billion, the business has soundly established itself in the industry. It
Medtronic Stock Is a Sell, According to 1 Wall Street Analyst
One week ago, medical device maker Medtronic (NYSE: MDT) surpassed Wall Street's sales and earnings targets. Despite the earnings beat, and despite giving guidance that mostly matched analysts'
Medtronic Stock Could Soar 29%, According to a Wall Street Analyst. Is the Dividend Champion a Buy Now?
Shares of Medtronic (NYSE: MDT) responded poorly to the company's latest quarterly results announcement. The market knocked the stock about 5% lower on May 23, but some analysts who follow the